These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 27632933)
21. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
22. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Tentori L; Portarena I; Vernole P; De Fabritiis P; Madaio R; Balduzzi A; Roy R; Bonmassar E; Graziani G Cancer Chemother Pharmacol; 2001 Apr; 47(4):361-9. PubMed ID: 11345654 [TBL] [Abstract][Full Text] [Related]
32. Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro. Somnay Y; Chen H; Kunnimalaiyaan M Neuroendocrinology; 2013; 97(2):183-92. PubMed ID: 22965070 [TBL] [Abstract][Full Text] [Related]
33. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301 [TBL] [Abstract][Full Text] [Related]
34. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. Senhaji Mouhri Z; Goodfellow E; Jean-Claude B BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752 [TBL] [Abstract][Full Text] [Related]
35. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. Lemasson B; Wang H; Galbán S; Li Y; Zhu Y; Heist KA; Tsein C; Chenevert TL; Rehemtulla A; Galbán CJ; Holland EC; Ross BD Neoplasia; 2016 Feb; 18(2):82-9. PubMed ID: 26936394 [TBL] [Abstract][Full Text] [Related]
37. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434 [TBL] [Abstract][Full Text] [Related]
39. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Barreto-Andrade JC; Efimova EV; Mauceri HJ; Beckett MA; Sutton HG; Darga TE; Vokes EE; Posner MC; Kron SJ; Weichselbaum RR Mol Cancer Ther; 2011 Jul; 10(7):1185-93. PubMed ID: 21571912 [TBL] [Abstract][Full Text] [Related]
40. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]